Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life.
AuthorBuchwald, Andrea G
Graham, Barney S
Haidara, Fadima Cheick
Lin, Bob C
Sow, Samba O
Levine, Myron M
Pasetti, Marcela F
Tapia, Milagritos D
JournalClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
PublisherOxford University Press
MetadataShow full item record
AbstractBACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of viral pneumonia and bronchiolitis during the first 6 months of life. Placentally transferred antibodies can prevent severe RSV illness, and maternal immunization may reduce illness in young infants. Identification of protective antibody levels facilitates the advancement of vaccine candidates and maternal immunization. METHODS: We conducted a nested case-control study with 587 Malian mother-infant pairs, followed from birth to age 6 months. RSV cases were infants who developed influenza-like illness (ILI) or pneumonia and were RSV-positive by polymerase chain reaction. Cases were matched to healthy controls and RSV-negative ILI controls. RSV-A and RSV-B neutralizing antibodies were measured in maternal, cord blood, and infant sera at age 3 and 6 months. RESULTS: Maternal antibodies were efficiently transferred to infants. Maternal and infant RSV titers were strongly correlated. Infant antibody titers against RSV-A were 3 times higher than those against RSV-B. At birth, infants who remained healthy had significantly higher RSV-A and RSV-B titers compared with infants who subsequently contracted RSV. RSV-A inhibitory concentration (IC)80 titer >239 or RSV-B titer >60 at birth was significantly associated with being a healthy control compared with an RSV case within the first 3 months of life. RSV-A IC80 titers in cord blood were associated with decreased episodes of pneumonia. CONCLUSIONS: Maternally acquired RSV antibodies were associated with protection of infants against community-detected cases of RSV-ILI and pneumonia. RSV titers in cord blood can predict whether an infant will be infected with RSV or remain uninfected.
Rights/Terms© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17525
- <i>In Vitro</i> Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.
- Authors: van Erp EA, van Kasteren PB, Guichelaar T, Ahout IML, de Haan CAM, Luytjes W, Ferwerda G, Wicht O
- Issue date: 2017 Nov 1
- Transplacental transfer of maternal respiratory syncytial virus (RSV) antibody and protection against RSV disease in infants in rural Nepal.
- Authors: Chu HY, Tielsch J, Katz J, Magaret AS, Khatry S, LeClerq SC, Shrestha L, Kuypers J, Steinhoff MC, Englund JA
- Issue date: 2017 Oct
- Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
- Authors: Blanco JCG, Fernando LR, Zhang W, Kamali A, Boukhvalova MS, McGinnes-Cullen L, Morrison TG
- Issue date: 2019 Dec 1
- Respiratory Syncytial Virus (RSV)-Specific Antibodies in Pregnant Women and Subsequent Risk of RSV Hospitalization in Young Infants.
- Authors: Koivisto K, Nieminen T, Mejias A, Capella Gonzalez C, Ye F, Mertz S, Peeples M, Ramilo O, Saxén H
- Issue date: 2022 Apr 1
- The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.
- Authors: Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, O'Brien KL
- Issue date: 2008 Mar